CoChat

CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma

Open access
Baird, John H., Frank, Matthew J., Craig, Juliana, Patel, Shabnum, Spiegel, Jay Y., Sahaf, Bita, Oak, Jean S., Younes, Sheren F., Ozawa, Michael G., Yang, Eric, Natkunam, Yasodha, Tamaresis, John, Ehlinger, Zachary, Reynolds, Warren D., Arai, Sally, Johnston, Laura, Lowsky, Robert, Meyer, Everett, Negrin, Robert S., Rezvani, Andrew R., Shiraz, Parveen, Sidana, Surbhi, Weng, Wen-Kai, Davis, Kara L., Ramakrishna, Sneha, Schultz, Liora, Mullins, Chelsea, Jacob, Allison, Kirsch, Ilan, Feldman, Steven A., Mackall, Crystal L., Miklos, David B., Muffly, Lori · 2021 · Blood
Cited by 79

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first 3 consecutive patients with autologous CAR19-refractory LBCL who were treated with a single infusion of autologous 1 × 106 CAR+ T cells per kilogram targeting CD22 (CAR22) as part of a phase 1 dose-escalation study. CAR22 therapy was relatively well tolerated, without any observed nonhematologic adverse events higher than grade 2. After infusion, all 3 patients achieved complete remission, with all responses continuing at the time of last follow-up (mean, 7.8 months; range, 6-9.3). Circulating CAR22 cells demonstrated robust expansion (peak range, 85.4-350 cells per microliter), and persisted beyond 3 months in all patients with continued radiographic responses and corresponding decreases in circulating tumor DNA beyond 6 months after infusion. Further accrual at a higher dose level in this phase 1 dose-escalation study is ongoing and will explore the role of this therapy in patients in whom prior CAR T-cell therapies have failed. This trial is registered on clinicaltrials.gov as #NCT04088890.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2020009432

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 79

Metadata

Authors
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., Oak, J. S., Younes, S. F., Ozawa, M. G., Yang, E., Natkunam, Y., Tamaresis, J., Ehlinger, Z., Reynolds, W. D., Arai, S., Johnston, L., Lowsky, R., Meyer, E., Negrin, R. S., Rezvani, A. R., Shiraz, P., Sidana, S., Weng, W.-K., Davis, K. L., Ramakrishna, S., Schultz, L., Mullins, C., Jacob, A., Kirsch, I., Feldman, S. A., Mackall, C. L., Miklos, D. B., & Muffly, L.
Venue
Blood
Published
2021-04-29
Volume
137
Issue
17
Pages
2321-2325
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W3116401648
Cited by
79
References
10
FWCI
4.49
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma. https://app.cochat.ai/papers/10.1182/blood.2020009432
The paper
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., Oak, J. S., Younes, S. F., Ozawa, M. G., Yang, E., Natkunam, Y., Tamaresis, J., Ehlinger, Z., Reynolds, W. D., Arai, S., Johnston, L., Lowsky, R., Meyer, E., Negrin, R. S., . . . Muffly, L. (2021). CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma. Blood. https://doi.org/10.1182/blood.2020009432

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.